li001

New BRAF-Mutated Colorectal Cancer Treatment

Targeted Therapy /

New first-line therapy has transformed treatment for BRAF V600E–mutated metastatic colorectal cancer (mCRC), an aggressive subtype with historically poor outcomes. FDA approval of the triple combination—encorafenib, cetuximab, and mFOLFOX6—marks a major breakthrough for these patients. The BREAKWATER trial demonstrated that this regimen doubled overall survival to 30.3 months compared with 15.1 months for standard therapy, […]

New BRAF-Mutated Colorectal Cancer Treatment Read More »

Advanced Cystoscopy for Early Bladder Cancer Diagnosis

Diagnostics /

New imaging techniques are improving cancer detection during cystoscopy, helping doctors identify and remove tumors more accurately. Blue Light Cystoscopy (BLC) with Cysview uses a photosensitizing agent, hexaminolevulinate HCl, instilled into the bladder about an hour before the procedure. Cancer cells absorb the agent and glow bright pink or red under blue light, while healthy

Advanced Cystoscopy for Early Bladder Cancer Diagnosis Read More »

New MRI Method Boosts Prostate Cancer Accuracy

Technology Innovation /

Investigators have found that multiparametric MRI (mpMRI) for prostate cancer becomes more accurate when lesion-level apparent diffusion coefficient (ADC) values and patient prostate-specific antigen density (PSAD) thresholds are incorporated. Stanford researchers reported their findings on August 12 in Radiology, showing that these additional metrics can improve the positive predictive value (PPV) of mpMRI for clinically

New MRI Method Boosts Prostate Cancer Accuracy Read More »

Advanced techniques in treatment of non-invasive bladder cancer

Treatment /

Recent advances in non-muscle-invasive bladder cancer (NMIBC) offer several innovative therapies, particularly for patients unresponsive to BCG treatment. These options leverage gene therapy, immune stimulation, oncolytic viruses, and novel drug delivery systems to improve outcomes. Nadofaragene firadenovec is an FDA-approved gene therapy that delivers a modified virus into bladder cells, prompting them to produce interferon

Advanced techniques in treatment of non-invasive bladder cancer Read More »

Breaking New Ground: Innovative Therapies Transforming Muscle-Invasive Bladder Cancer Treatment

Treatment /

Recent advances in muscle-invasive bladder cancer (MIBC) have expanded treatment options, particularly for high-risk and metastatic disease. Combination therapy with Enfortumab vedotin and Pembrolizumab is now a first-line option for advanced bladder cancer. Enfortumab vedotin delivers chemotherapy directly to tumor cells, while pembrolizumab activates the immune system to recognize and attack cancer. Adjuvant immunotherapy with

Breaking New Ground: Innovative Therapies Transforming Muscle-Invasive Bladder Cancer Treatment Read More »

New Technology in Early Diagnosis of Blaccer Cancer

Diagnostics /

Recent innovations in bladder cancer diagnostics are improving detection, monitoring, and treatment planning while reducing invasive procedures. Contrast-enhanced ultrasound (CEUS) uses microbubble agents to visualize blood flow within tumors, helping distinguish non-invasive from invasive bladder cancers. Advances like 3D CEUS are also being explored to evaluate tumor response during therapy. Advanced imaging with PET-CT or

New Technology in Early Diagnosis of Blaccer Cancer Read More »

Nivolumab and Ipilimumab Combination Therapy: Dual Checkpoint Inhibition in Advanced Malignancies

Treatment /

The combination of Nivolumab and Ipilimumab is a groundbreaking immunotherapy that helps the immune system attack cancer. Ipilimumab “primes” T-cells by blocking the early CTLA-4 checkpoint, allowing more immune cells to prepare for action, while nivolumab “unleashes” them by inhibiting the PD-1 checkpoint, preventing cancer cells from hiding. Together, they create a powerful, synergistic immune

Nivolumab and Ipilimumab Combination Therapy: Dual Checkpoint Inhibition in Advanced Malignancies Read More »

Non-surgical treatment for HPV-positive throat cancer

Rare Cancers /

Non-surgical treatment is increasingly effective for HPV-positive throat cancer, which responds well to radiation and chemotherapy. Avoiding surgery can reduce long-term side effects and improve quality of life for patients who are likely long-term survivors. Radiation therapy remains a cornerstone, with advances in de-escalated dosing that maintain effectiveness while minimizing debilitating side effects. Chemotherapy, alone

Non-surgical treatment for HPV-positive throat cancer Read More »

Non-radiation Ablative Therapies: Clinical Application

Technology Innovation /

Non-radiation ablative therapies are minimally invasive, image-guided procedures that destroy localized tumors using energy sources other than ionizing radiation. They are particularly valuable for patients who cannot undergo surgery or prefer less invasive options. In liver cancer, ablative therapies are standard for early-stage hepatocellular carcinoma (HCC) under 3–5 cm, with outcomes comparable to surgery. Techniques

Non-radiation Ablative Therapies: Clinical Application Read More »

Pembrolizumab: Revolutionizing Cancer Treatment Across Multiple Tumor Types

Treatment /

Pembrolizumab is a pioneering checkpoint inhibitor that empowers the immune system to fight cancer by blocking PD-1 receptors on T-cells. Normally, cancer cells exploit PD-L1 to turn off T-cells, evading immune attack. Pembrolizumab removes this “brake,” allowing T-cells to recognize and destroy tumors. This approach shifts cancer therapy from directly targeting cells to enhancing the

Pembrolizumab: Revolutionizing Cancer Treatment Across Multiple Tumor Types Read More »